



| IEHP UM Subcommittee Approved Authorization Guideline | | | |
|---|-----------------------------|--------------------------------|--------------|
| Guideline | Antepartum Fetal Assessment | Guideline # | UM_GYN 01 |
| | | Original Effective Date | 4/21/2005 |
| Section | Gynecology/Obstetrics | Revision Date | 3/26/2018 |

COVERAGE POLICY

A referral to a high-risk OB provider must include a high-risk indication together with appropriate diagnosis codes and clinical notes or labs to establish the medical necessity of the request.

“Antepartum fetal assessment” as defined in this document refers to ultrasonography and noninvasive assessments of fetal well-being – these assessments (e.g., biophysical profile, non-stress test, amniotic fluid adequacy) are described below. The frequency of antepartum assessments and the types of tests utilized will be evaluated based on Attachment A.

Per Medi-Cal guidelines, “Ultrasound performed for routine screening during pregnancy is considered an integral part of patient care during pregnancy and its reimbursement is included in the obstetrical fee. Ultrasound during pregnancy is reimbursable only when used for the diagnosis or treatment of specific medical conditions.” [1]

Prior authorization is required for any additional ultrasound beyond an NT and anatomy scan. Appropriate medical record documentation of **medical necessity** must accompany the prior authorization request. Failure to obtain prior authorization for ultrasound beyond the NT and routine anatomy studies (as described above) will lead to denial of charges.

No authorization is needed for the routine anatomy ultrasound between 18 and 22 weeks of gestation as long as the member is not under the care of a maternal-fetal medicine (MFM) specialist for a high-risk condition. Appropriate CPT codes for these ultrasounds are:

1. 76805 for a routine anatomy ultrasound
2. 76801 for an ultrasound performed by an MFM specialist for a high-risk condition before 14 weeks of gestation
3. 76811 (“detailed fetal anatomic ultrasound evaluation”) for an ultrasound performed by an MFM specialist for a high-risk condition after 14 weeks of gestation

Note that only one initial ultrasound (CPT code 76805, 76801, or 76811) is paid per provider per pregnancy and; any ultrasound thereafter is considered a follow up ultrasound (CPT code 76816).

There are various types of dopplers that can be performed in the antepartum period. However, maternal uterine artery dopplers are currently not indicated for any condition and thus, not covered.

An MFM specialist may perform a modified biophysical profile (BPP) when indicated by a condition listed in the Attachment A schedule. The modified BPP consists of a fetal non-stress test (NST) and evaluation of amniotic fluid adequacy using a measure of the deepest vertical pocket (DVP) of amniotic fluid by ultrasonography. [4] (The DVP measure is now preferred over the amniotic fluid index – AFI -for the diagnosis of abnormalities in the quantity of amniotic fluid.) [4] A “reactive” modified BPP test supports the absence of fetal distress (high negative predictive value). [4]

We recognize that these are guidelines and exceptions will occur. Feel free to contact IEHP’s Utilization Management department with questions or problematic cases.

COVERAGE LIMITATIONS AND EXCLUSIONS

IEHP will cover only two (2) ultrasounds in the uncomplicated Medi-Cal pregnancy: a nuchal translucency (NT) scan performed between 11 weeks 2 days and 14 weeks 2 days of gestation, and a routine anatomy ultrasound performed ideally between 18 weeks and 22 weeks of gestation. [2,3] Other ultrasounds performed in an uncomplicated pregnancy will be denied as a non-covered benefit. Any ultrasound performed in a pregnancy beyond the NT and anatomy ultrasounds must include the appropriate ICD-10-CM code and documentation indicating a high-risk condition affecting the pregnancy.

Attachment A:

| Maternal High-Risk Conditions in the Antepartum Evaluation | | | |
|---|--|---|---|
| Condition | Modified BPP Schedule | Ultrasound Surveillance | Comments |
| Maternal age (≥ 40 years at time of birth) [5,6] | Twice weekly starting at 38 weeks of gestation | None | |
| Anemia [4,7] | None | None | See separate entry for maternal sickle cell disease |
| Asthma [8] | | | |
| Mild intermittent asthma that is controlled with medications | None | None | |
| Mild persistent asthma, moderate persistent asthma, severe persistent asthma, or any classification that is poorly controlled | Weekly Starting at 32 weeks of gestation | Every 4 weeks Starting at 28 weeks (assessing fetal growth) | |
| Antiphospholipid antibody syndrome [4,9] | Twice weekly Starting at 32 weeks of gestation | Every 4 weeks Starting at 28 weeks (assessing fetal growth) | |

| | | | |
|--|---|--|--|
| Bariatric surgery prior to pregnancy [10] | None | Every 4 weeks Starting at 28 weeks (assessing fetal growth) | See separate entry for maternal obesity |
| Cerclage in current or prior pregnancy [11] | None | None | Provider may conduct: One transvaginal ultrasound to confirm location after initial cerclage placement Subsequent transvaginal ultrasound surveillance of cervical length is <u>not</u> recommended in the presence of cerclage |
| Cholestasis of pregnancy [12,13] | Twice weekly Starting at diagnosis, no earlier than 28 weeks | None | |
| Congenital heart disease (maternal, paternal OR in sibling of the fetus) [14] | None | Detailed fetal anatomic ultrasound examination between 18 and 22 weeks | See IEHP UM Guidelines for fetal echocardiography |
| Cystic fibrosis carrier | None | None | |
| Diabetes [15] | | | |
| White Class A1 (gestational, diet-controlled) – in <u>good</u> control | None | One ultrasound to assess fetal growth at 28-32 weeks | |
| White Class A1 (gestational, diet-controlled) – in poor control OR White Class A2 (gestational, medication-controlled) OR White Class B (pre-gestational) or greater | Twice weekly Starting at 32 weeks | Every 4 weeks Starting at 28 weeks | |
| Excisional procedure of the cervix prior to pregnancy [16,17] | None | None | |

| | | | |
|---|--|---|---|
| Fibroids (leiomyomata) [18] | None | Ultrasound at 28-32 weeks to assess fetal growth | |
| Gestational trophoblastic disease in a prior pregnancy [19] | None | None | |
| Any Hypertensive disorders in pregnancy: <ul style="list-style-type: none"> • Chronic hypertension • Gestational hypertension • Preeclampsia with or without severe features, superimposed preeclampsia) | Twice weekly Starting at 32 weeks | Every 4 weeks Starting at 28 weeks | See separate entries for associated complications (e.g., fetal growth restriction, maternal antiphospholipid antibody syndrome, maternal lupus) <u>Note:</u> uterine artery dopplers (assessing for increased resistance or “notching” are not recommended for screening or management in women with hypertensive disorders of pregnancy |
| Infectious exposures in pregnancy | | | |
| Cytomegalovirus [21] Or Varicella | None | Detailed fetal anatomic ultrasound examination between 18 and 22 weeks Repeat every 4 weeks to assess fetal growth Starting at 28 weeks | |
| Parvovirus B19 [21] | Twice weekly Starting at 28 weeks, in the setting of associated fetal anemia or hydrops | Every 2 weeks for 8-12 weeks following exposure | Ultrasounds may be accompanied by fetal middle cerebral artery peak systolic velocity (Doppler) assessments in the setting of associated fetal anemia or hydrops |
| Toxoplasmosis [21] | None | Detailed fetal anatomic ultrasound examination | |

| | | | |
|--|-----------------------------------|--|--|
| | | between 18 and 22 weeks. Repeat every 2-4 weeks to assess fetal growth Starting at 28 weeks | |
| Zika virus [22] | Twice weekly Starting at 28 weeks | Detailed fetal anatomic ultrasound examination between 18 and 22 weeks Repeat every 2-4 weeks to assess fetal growth, possible microcephaly Starting at 28 weeks | |
| Listeria – asymptomatic [23] | None | None | |
| Listeria – symptomatic [23] | Twice weekly Starting at 28 weeks | Detailed fetal anatomic ultrasound examination between 18 and 22 weeks. Repeat at 28-32 weeks to assess fetal growth | |
| Late prenatal care [24] (Gestation after 20 weeks) | Twice weekly Starting at 39 weeks | One ultrasound for pregnancy dating Repeat within 4 weeks to assess fetal growth | |
| Late term pregnancy (>41 weeks) [25] OR post dates | Twice weekly | None | |
| Low-lying placenta | None | One ultrasound at 24-28 weeks to assess placental location If low-lying placenta noted at 24-28 weeks, repeat once in 4 | Transvaginal ultrasound preferred for both instances described |

| | | | |
|--|--|--|--|
| | | weeks to reassess placental location | |
| Lupus [26] | Twice weekly starting at 28 weeks of gestation | Every 4 weeks, to assess fetal growth Starting at 28 weeks | |
| Missed serum genetic screening [24] | None | None | See separate entry for late prenatal care |
| Obesity (body mass index – BMI - >30 kg/m²) [27-30] | For BMI>40 kg/m ² : Twice weekly Starting at 32 weeks | Detailed fetal anatomic ultrasound evaluation at 20-22 weeks May repeat once in 2-4 weeks if anatomic views are limited due to maternal habitus Repeat at 32-36 weeks to assess fetal growth | |
| Placenta previa | | | |
| No prior uterine scar (e.g., myomectomy, cesarean birth) [3] OR Prior uterine scar (e.g., myomectomy, cesarean birth) [31] | None | Once at 24-28 weeks to assess placental location Repeat at 34-36 weeks to reassess placental location | Transvaginal ultrasound (to assess placental location) and transabdominal ultrasound (to assess for placenta accreta) preferred for both instances described |
| Placental abruption in a prior pregnancy | None | None | See entry for prior stillbirth, if applicable |
| Preterm birth in a prior pregnancy – specifically, prior spontaneous birth of a singleton gestation at <37 weeks [16,17] | None | Initial cervical length screening between 16-24 weeks Repeat every 2 weeks until 24 weeks | Transvaginal ultrasound preferred for all instances |
| Prolactinoma | None | None | |

| Psychiatric disorders [32] | | | |
|--|---|--|--|
| Anxiety or depression, on no medications OR exposure to selective serotonin reuptake inhibitors/selective norepinephrine reuptake inhibitors OR Any psychiatric diagnosis with exposure to antipsychotic medications | None | None | |
| Anxiety or depression with exposure to paroxetine OR Anxiety with exposure to benzodiazepines OR Any psychiatric diagnosis, with exposure to antiepileptic medications | None | Detailed fetal anatomic ultrasound evaluation at 18-22 weeks | See IEHP UM Subcommittee Approved Authorization Guidelines for Fetal Echocardiography for paroxetine |
| Seizure- No medication [32] | None | None | |
| Seizure- on antiepileptics [32] | None | Detailed fetal anatomic ultrasound evaluation at 12-22 weeks | |
| Sickle cell [7.4] | | | |
| Trait | None | None | |
| Disease [33] | Weekly Starting at 32 weeks | Every 4 weeks Starting at 28 weeks | See separate entry for fetal growth restriction, if applicable |
| Stillbirth (fetal loss at >20 weeks) in a prior pregnancy [34] | Weekly Starting 2 weeks prior to gestational age at prior stillbirth, no | None | |

| | | | |
|--|---|--|--|
| | earlier than 32 weeks | | |
| Substance use – during any point in the pregnancy | | | |
| Opioids, methamphetamines, cocaine (or its derivatives) | Twice weekly Starting at 32 weeks | Every 4 weeks to assess fetal growth Starting at 28 weeks | See separate entry for fetal growth restriction, if applicable |
| Alcohol or tobacco OR Marijuana (or its derivatives) | None | Every 4 weeks to assess fetal growth Starting at 28 weeks | See separate entry for fetal growth restriction, if applicable |
| Third trimester vaginal bleeding | Once at diagnosis May repeat as needed | Ultrasound to evaluate placental location | Transvaginal ultrasound preferred |
| Thrombocytopenia [36] | | | |
| Gestational | None | None | |
| Maternal immune thrombocytopenia | None | Every 4 weeks to assess fetal growth Starting at 28 weeks | |
| Thrombophilia (i.e., Factor V Leiden mutation carrier, Prothrombin G20210 mutation carrier, Protein C deficiency, Protein S deficiency, Antithrombin deficiency) [37] | Weekly starting at 32 weeks | Ultrasound to assess fetal growth at 28-32 weeks | See separate entry for fetal growth restriction, if applicable |
| Thyroid disease [38] | | | |
| Hypothyroidism, controlled on medication | None | None | |
| Hyperthyroidism, controlled on medication | None | Every 4 weeks Starting at 28 weeks | |
| Uncontrolled hyperthyroidism OR hypothyroidism | Twice weekly Starting at 32 weeks | Every 4 weeks Starting at 28 weeks | |
| Vasa previa [39] | None | Every 4 weeks Starting at 28 weeks | Transvaginal and transabdominal ultrasound preferred |
| Velamentous cord insertion [40] | None | Every 4 weeks | |

| | | | |
|--|--|----------------------|--|
| | | Starting at 28 weeks | |
|--|--|----------------------|--|

| Fetal High Risk Conditions in the Antepartum Evaluation | | | |
|---|--|--|---|
| Condition | Modified BPP Schedule | Ultrasound Surveillance | Comments |
| Abnormal first or second trimester serum analytes, in the setting of normal karyotype and normal fetal anatomy (i.e.: + AFP, elevated HCG or unconjugated estriol) [41] | None | Ultrasound to assess fetal growth at 28-32 weeks | See separate entry for fetal growth restriction, if applicable |
| Rh alloimmunization OR other minor antibodies (e.g., Lewis) OR Kell antibodies OR Non-immune anemia or hydrops – due to fetal cardiac anomaly, fetal arrhythmia or congenital infection [42] | Twice weekly Starting at diagnosis, no earlier than 24 weeks | Every 2-4 weeks Starting at 28 weeks | Ultrasounds may be accompanied by fetal middle cerebral artery peak systolic velocity (Doppler) assessments |
| Arrhythmia [43] | | | |
| Premature atrial contractions | None | None | |
| Tachyarrhythmia or heart block | Twice weekly Starting at diagnosis, no earlier than 24 weeks | Every 4 weeks Starting at 28 weeks | See separate entry for associated non-immune hydrops |
| Breech presentation [44] | None | None | |
| Decreased fetal movement [4] | At time of complaint May repeat once within the following 48 hours, then as needed Starting no earlier than 28 weeks | None | |

| Fetal congenital anomaly | | | |
|---|---|---|---|
| Isolated choroid plexus cyst [45] OR Isolated echogenic intracardiac focus [46] OR Isolated renal pelviectasis (>4 mm in the second trimester or >7 mm in the third trimester) [48] OR Isolated short humerus or femur [41] | None | Detailed fetal anatomic ultrasound evaluation at 18-22 weeks Repeat at 28-32 weeks | |
| Isolated echogenic bowel [47] | Weekly Starting at 32 weeks | Detailed fetal anatomic ultrasound evaluation (CPT 76811) at 18-22 weeks Repeat ultrasound evaluation at 28-32 weeks | |
| Isolated single umbilical artery [49] | None | Detailed fetal anatomic ultrasound evaluation at 18-22 weeks Repeat ultrasound at 28-32 weeks to assess fetal growth | |
| Isolated cleft lip and/or cleft palate OR Isolated clubbed foot/feet | None | Repeat ultrasound evaluation at 28-32 weeks | |
| Fetal growth restriction (or “intrauterine growth restriction”) [3,50] | Twice weekly Starting at diagnosis, no earlier than 24 weeks | Detailed fetal anatomic ultrasound evaluation to assess for fetal congenital anomalies at time of diagnosis Then every 2-4 weeks Starting at 28 weeks | Approve umbilical artery doppler if requested by the provider |
| Macrosomia (suspected; estimated fetal weight >4,000 g at term) | None | None | See separate entry for size-dates discrepancy |
| Multiple gestation [51] | | | |

| | | | |
|--|--|---|--|
| Dichorionic with concordant growth | Twice weekly starting at 32 weeks | Every 4 weeks Starting at 16 weeks | |
| Dichorionic with discordant growth (estimated inter-fetal weight difference of $\geq 20\%$) OR Monochorionic with concordant growth OR Monochorionic with discordant growth | Twice weekly Starting at 28 weeks in the absence of complications May begin at the time of diagnosis of a related complication (e.g., twin-twin transfusion syndrome) | Every 2 weeks Starting at 16 weeks | |
| Loss of one twin, diagnosed after 12 weeks of gestation | None | 4 weeks after diagnosis of fetal loss | No further imaging or testing indicated if loss diagnosed before 12 weeks of gestation |
| Nuchal cord | None | None | |
| Nuchal fold abnormal (>6 mm) in the second trimester, in the setting of normal karyotype [52] OR Nuchal translucency abnormal (>3 mm) in the first trimester, in the setting of normal karyotype [41] | None | Detailed fetal anatomic ultrasound evaluation at 18-22 weeks Repeat ultrasound evaluation at 28-32 weeks | See IEHP UM guidelines for fetal echocardiography |
| Oligohydramnios [53] | | | |
| Isolated | Twice weekly Starting at diagnosis, no earlier than 24 weeks | Every 2-4 weeks Starting at 28 weeks | |
| In the presence of another fetal or maternal complication | None | None | See entries for other associated fetal or maternal complications |
| Polyhydramnios | Twice weekly Starting at 32 weeks | Detailed fetal anatomic ultrasound evaluation to assess | See entry for diabetes if associated with finding of polyhydramnios |

| | | | |
|---|------|--|--|
| | | for fetal congenital anomalies Then every 4 weeks Starting at 28 weeks | |
| Size-dates discrepancy (>2 cm discrepancy between gestational age in weeks and fundal height in cm) [3] | None | One ultrasound at diagnosis to evaluate fetal growth | |

ADDITIONAL INFORMATION

Pregnancy-Related Office Visits: Consultants who co-manage a pregnancy without complete transfer of care should not bill with code Z1032 (initial pregnancy-related office visit). Instead, code Z1034 (per-visit antepartum office visit) should be used.

Pregnancy: Per-Visit Billing

A provider who does not render total obstetrical care during the recipient’s entire pregnancy, or who renders fewer than four antepartum visits, must bill each visit or procedure separately. Each visit is subject to the six-month billing limit. Recipient eligibility must be verified for each month of service.

Antepartum Visits HCPCS code Z1034 is used for billing antepartum visits and is reimbursable only when obstetrical care is billed on a per-visit basis. Reimbursement for antepartum visits is limited to eight visits in a nine-month period. Providers may bill more than eight antepartum follow-up visits in nine months if the provider documents a second pregnancy within those nine months.

CLINICAL/REGULATORY RESOURCE

N/A

DEFINITION OF TERMS

Definitions: Non-invasive Assessments of Fetal Well-Being [42]

Nonstress Test (NST): The NST is based on the premise that the heart rate of a fetus that is not acidotic or neurologically depressed will temporarily accelerate with fetal movement. Heart rate reactivity is thought to be a good indicator of normal fetal autonomic function. Loss of reactivity is most commonly associated with a fetal sleep cycle but may result from any cause of central nervous system depression, including fetal acidemia. The patient may be positioned in either the semi-Fowler position (sitting with the head elevated 30 degrees) or lateral recumbent position. The fetal heart rate (FHR) is monitored with an external transducer. The tracing is observed for FHR accelerations that peak (but do not necessarily remain) at least 15 beats per minute above the baseline and last 15 seconds from baseline to baseline. The NST should be conducted for at least 20 minutes, but it may be necessary to monitor the tracing for 40 minutes or longer to take into account the variations of the fetal sleep–wake cycle. Nonstress test results are categorized as reactive or nonreactive. Various definitions of reactivity have been used. The most common definition of a reactive, or normal, NST is if there are two or more FHR accelerations (as previously defined) within a 20-minute period. A nonreactive NST is one that lacks sufficient FHR accelerations over a 40-minute period.

Amniotic Fluid Adequacy: The currently preferred measure of amniotic fluid adequacy is the “deepest vertical pocket” (DVP) measurement. A DVP of at least 2 cm of amniotic fluid is normal; a DVP of less than 2 cm is considered abnormal (referred to as “oligohydramnios”). Amniotic fluid index (AFI) is the sum of measurements of the deepest umbilical-cord free amniotic fluid pockets in the four uterine quadrants. The AFI is considered normal if it is greater than 5 cm and abnormal if it is 5cm or less (again, “oligohydramnios”).

Biophysical Profile (BPP): The BPP is comprised of an NST in addition to four (4) observations made by real-time ultrasonography. The five (5) components of the BPP follow – each component is given a score of 2. A composite score of 8-10 is considered normal (i.e., continued expectant management of the pregnancy is acceptable).

1. NST (as previously described)
2. Fetal breathing movements
3. Fetal movements
4. Fetal tone
5. Determination of adequate amniotic fluid volume (normal DVP)

Contraction Stress Test (CST): The CST is based on the response of the FHR to uterine contractions. It relies on the premise that fetal oxygenation will be transiently worsened by uterine contractions. With the patient in the lateral recumbent position, the FHR and uterine contractions are simultaneously recorded with an external fetal monitor. An adequate uterine contraction pattern is present when at least three contractions persist for at least 40 seconds each in a 10-minute period. Uterine stimulation is not necessary if the patient is having spontaneous uterine contractions of adequate frequency. If fewer than three contractions of 40 seconds’ duration occur in 10 minutes, contractions are induced with either nipple stimulation or intravenous oxytocin.

The CST is interpreted according to the presence or absence of late FHR decelerations. The results of the CST are categorized as follows:

1. Negative: no late or significant variable decelerations
2. Positive: late decelerations after 50% or more of contractions (even if the contraction frequency is fewer than three in 10 minutes)
3. Equivocal–suspicious: intermittent late decelerations or significant variable decelerations
4. Equivocal: FHR decelerations that occur in the presence of contractions more frequent than every 2 minutes or lasting longer than 90 seconds
5. Unsatisfactory: fewer than three contractions in 10 minutes or an uninterpretable tracing

Recommendations:

When the clinical condition that prompted testing persists, a reassuring test should be repeated weekly or twice weekly until delivery, depending on the test used and the presence of certain high-risk pregnancy conditions. Any presumed significant change in fetal well-being requires fetal re-evaluation, regardless of the interval since the most recent test.

An abnormal NST or modified BPP usually should be further evaluated using other tests (e.g., CST, full BPP). Subsequent management should then be predicated on the results of subsequent tests (indicating fetal compromise), the gestational age, the presence or absence of oligohydramnios (if assessed), and the maternal condition.

Recent, normal antepartum fetal test results should not preclude the use of intrapartum fetal monitoring.

REFERENCES

1. Med-Cal - Title 22. Pregnancy: Early Care and Diagnostic Services. Available at: https://files.medi-cal.ca.gov/pubsdoco/publications/masters.../pregearly_m00o03.doc. Retrieved July 27, 2017.
2. California Department of Public Health (CDPH). Prenatal Screening Calculator. 2017. Available at: <https://archive.cdph.ca.gov/programs/pns/Pages/prenatalscreeningcalculator.aspx>. Retrieved July 27, 2017.
3. American College of Obstetricians and Gynecologists (ACOG) and the American Institute of Ultrasound in Medicine (AIUM). Practice Bulletin No. 175: Ultrasound in Pregnancy. *Obstet Gynecol.* 2016;128(6):e241-e256.
4. ACOG. Practice Bulletin No. 145: Antepartum Fetal Surveillance. *Obstet Gynecol.* 2014;124(1):182-92.
5. Society for Maternal-Fetal Medicine (SMFM). Publications and Guidelines: Advanced maternal age and the risk of antepartum stillbirth. 2014. Available at: <https://www.smfm.org/publications/81-advanced-maternal-age-and-the-risk-of-antepartum-stillbirth>. Retrieved July 27, 2017.
6. Fretts RC, Duru UA. New indications for antepartum testing: making the case for antepartum surveillance or timed delivery for women of advanced maternal age. *Semin Perinatol.* 2008;32(4):312-7.
7. ACOG. Practice Bulletin No. 95: Anemia in Pregnancy. *Obstet Gynecol.* 2008;112(1):201-7.
8. ACOG. Practice Bulletin No. 90: Asthma in Pregnancy. *Obstet Gynecol.* 2008;111(2 pt 1):457-64.
9. ACOG. Practice Bulletin No. 132: Antiphospholipid Syndrome. *Obstet Gynecol.* 2012;120(6):1514-21.
10. ACOG. Practice Bulletin No. 105: Bariatric Surgery and Pregnancy. *Obstet Gynecol.* 2009;113(6):1405-13.
11. ACOG. Practice Bulletin No. 142: Cerclage for the Management of Cervical Insufficiency. *Obstet Gynecol.* 2014;123(2 pt 1):372-9.
12. Williamson C, Geenes V. Intrahepatic cholestasis of pregnancy. *Obstet Gynecol.* 2014;124(1):120-33.
13. Society for Maternal-Fetal Medicine (SMFM). Publications and Guidelines: Understanding intrahepatic cholestasis of pregnancy. 2011. Available at: <https://www.smfm.org/publications/96-understanding-intrahepatic-cholestasis-of-pregnancy>. Retrieved July 27, 2017.
14. Canobbio MM, Warnes CA, Aboulhosn J, Connolly HM, Khanna A, Koos BJ, Mital S, Rose C, Silversides C, Stout K. Management of Pregnancy in Patients with Complex Congenital Heart Disease: A Scientific Statement for Healthcare Professionals From the American Heart Association. *Circulation.* 2017;135:e50-87.
15. ACOG. Practice Bulletin No. 180: Gestational Diabetes Mellitus. *Obstet Gynecol.* 2017;130(1):e17-37.
16. ACOG. Practice Bulletin No. 130: Prediction and Prevention of Preterm Birth. *Obstet Gynecol.* 2012;120(4):964-73.
17. McIntosh J, Feltovich H, Berghella V, Manuck T. The role of routine cervical length screening in selected high- and low-risk women for preterm birth prevention. *Am J Obstet Gynecol.* 2016 Sep;215(3):B2-7.

18. Lee HJ, Norwitz ER, Shaw J. Contemporary Management of Fibroids in Pregnancy. *Reviews in Obstetrics and Gynecology*. 2010;3(1):20-27.
19. ACOG. Practice Bulletin No. 53: Diagnosis and treatment of gestational trophoblastic disease. *Obstet Gynecol*. 2004;93(3):575-85.
20. ACOG. Hypertension in Pregnancy Task Force. 2013. Available at: <https://www.acog.org/~media/Task%20Force%20and%20Work%20Group%20Reports/public/HypertensioninPregnancy.pdf>. Retrieved July 27, 2017.
21. ACOG. Practice Bulletin No. 151: Cytomegalovirus, parvovirus B19, varicella zoster, and toxoplasmosis in pregnancy. *Obstet Gynecol*. 2015;125(6):1510-25.
22. SMFM. Statement: Ultrasound screening for fetal microcephaly following Zika virus exposure. *Am J Obstet Gynecol*. 2016;214(6):B2-4.
23. ACOG. Committee Opinion No. 614: Management of pregnant women with presumptive exposure to *Listeria monocytogenes*. *Obstet Gynecol*. 2014;124(6):1241-4.
24. ACOG. Committee Opinion No. 688: Management of Suboptimally Dated Pregnancies. *Obstet Gynecol*. 2017;129(5):967-8.
25. ACOG. Practice Bulletin No. 146: Management of late-term and postterm pregnancies. *Obstet Gynecol*. 2014;124(2 pt 1):390-6.
26. Andreoli L et al. Extended Report: report EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. *Ann Rheum Dis*. 2017;76(3):476-85.
27. ACOG. Practice Bulletin No. 156: Obesity in Pregnancy. *Obstet Gynecol* 2015;126(6):e112-26.
28. Branum AM, Kirmeyer SE, Gregory ECW. Prepregnancy Body Mass Index by Maternal Characteristics and State: Data From the Birth Certificate, 2014. *Natl Vital Stat Rep*. 2016;65(6):1-11.
29. SMFM and AIUM. 76811 Task Force. Consensus Report on the Detailed Fetal Anatomic Ultrasound Evaluation: Indications, Components, and Qualifications. *J Ultrasound Med*. 2014;33:189-95.
30. Reddy UM, Abuhamad AZ, Levine D, Saade GR for the Fetal Imaging Workshop Invited Participants. Fetal Imaging: Executive Summary of a Joint Eunice Kennedy Shriver National Institute of Child Health and Human Development, SMFM, AIUM, ACOG, American College of Radiology, Society for Pediatric Radiology, and Society of Radiologists in Ultrasound. *Obstet Gynecol*. 2014;123:1070-82.
31. ACOG. Committee Opinion No. 529: Placenta accreta. *Obstet Gynecol*. 2012;120(1):207-11.
32. ACOG. Practice Bulletin No. 92: Use of psychiatric medications during pregnancy and lactation. *Obstet Gynecol*. 2008;111(4):1001-20.
33. ACOG. Practice Bulletin No. 78: Hemoglobinopathies in pregnancy. *Obstet Gynecol*. 2007;109(1):229-37.
34. ACOG. Practice Bulletin No. 102: Management of stillbirth. *Obstet Gynecol*. 2009;113(3):748-61.
35. Reddy UM, Davis JM, Ren Z, Greene MF. Opioid Use in Pregnancy, Neonatal Abstinence Syndrome, and Childhood Outcomes: Executive Summary of a Joint Workshop by the Eunice Kennedy Shriver National Institute of Child Health and Development. *Obstet Gynecol*. 2017;130(1):10-28.
36. ACOG. Practice Bulletin No. 166: Thrombocytopenia in pregnancy. *Obstet Gynecol*. 2016;128(3):e43-53.

37. ACOG. Practice Bulletin No. 138: Inherited thrombophilias in pregnancy. *Obstet Gynecol.* 2013;122(3):706-17.
38. ACOG. Practice Bulletin No. 148: Thyroid disease in pregnancy. *Obstet Gynecol.* 2015;125(4):996-1005.
39. SMFM. Publications and Guidelines: Diagnosis and management of vasa previa. 2015. Available at: <https://www.smfm.org/publications/215-diagnosis-and-management-of-vasa-previa>. Retrieved July 27, 2017.
40. Vintzileos AM, Ananth CV, Smulian JC. Using ultrasound in the clinical management of placental implantation abnormalities. *Am J Obstet Gynecol.* 2015;213(4):S70-7.
41. ACOG. Practice Bulletin No. 163: Screening for fetal aneuploidy. *Obstet Gynecol.* 2016;127(5):979-81.
42. Norton ME, Chauhan SP, Dashe JS. SMFM clinical guideline #7: Nonimmune hydrops fetalis. *Am J Obstet Gynecol.* 2015;212(2):127-39.
43. Maeno Y, Hirose A, Kanbe T, Hori D. Fetal arrhythmia: prenatal diagnosis and perinatal management. *J Obstet Gynaecol Res.* 2009;35(4):623-9.
44. ACOG. Practice Bulletin No. 161: External cephalic version. *Obstet Gynecol.* 2016;127(3):e54-61.
45. SMFM. Publications and Guidelines: Isolated fetal choroid plexus cysts. 2013. Available at: <https://www.smfm.org/publications/74-isolated-fetal-choroid-plexus-cysts>. Retrieved July 27, 2017.
46. SMFM. Publications and Guidelines: Isolated echogenic intracardiac focus. 2013. Available at: <https://www.smfm.org/publications/73-isolated-echogenic-intracardiac-focus>. Retrieved July 27, 2017.
47. SMFM. Publications and Guidelines: Isolated echogenic bowel diagnosed on second-trimester ultrasound. 2011. Available at: <https://www.smfm.org/publications/93-isolated-echogenic-bowel-diagnosed-on-second-trimester-ultrasound>. Retrieved July 27, 2017.
48. SMFM. Publications and Guidelines: Evaluation and management of isolated renal pelviectasis diagnosed on second trimester ultrasound. Available at: <https://www.smfm.org/publications/90-evaluation-and-management-of-isolated-renal-pelviectasis-diagnosed-on-second-trimester-ultrasound>. Retrieved July 27, 2017.
49. SMFM. Publications and Guidelines: Single umbilical artery: What you need to know. 2010. Available at: <https://www.smfm.org/publications/104-single-umbilical-artery-what-you-need-to-know>. Retrieved July 27, 2017.
50. ACOG. Practice Bulletin No. 134: Fetal growth restriction. *Obstet Gynecol.* 2013;121(5):1122-33.
51. ACOG. Practice Bulletin No. 169: Multifetal gestations: Twin, triplet, and higher-order multifetal pregnancies. *Obstet Gynecol.* 2016;128(4):e131-46.
52. Odibo AO, Ghidni A. Role of the second-trimester 'genetic sonogram' for Down syndrome screen in the era of first-trimester screening and non-invasive prenatal testing. *Prenatal Diagnosis.* 2014;34:511-7.
 Rabie N, Magann E, Steelman S, Ounpraseuth S. Oligohydramnios in complicated and uncomplicated pregnancy: a systematic review and meta-analysis. *Ultrasound Obstet Gynecol.* 2017;49(4):442-449.

DISCLAIMER

IEHP Clinical Authorization Guidelines (CAG) are developed to assist in administering plan benefits, they do not constitute a description of plan benefits. The Clinical Authorization Guidelines (CAG) express IEHP's determination of whether certain services or supplies are medically necessary, experimental and investigational, or cosmetic. IEHP has reached these conclusions based upon a review of currently available clinical information (including clinical outcome studies in the peer-reviewed published medical literature, regulatory status of the technology, evidence-based guidelines of public health and health research agencies, evidence-based guidelines and positions of leading national health professional organizations, views of physicians practicing in relevant clinical areas, and other relevant factors). IEHP makes no representations and accepts no liability with respect to the content of any external information cited or relied upon in the Clinical Authorization Guidelines (CAG). IEHP expressly and solely reserves the right to revise the Clinical Authorization Guidelines (CAG), as clinical information changes.